10-Q quarterly report · filed Nov 4, 2026

OPKO HEALTH, INC. (OPK) Q3 2026 10-Q Quarterly Report

Short answer

OPKO HEALTH, INC. (OPK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$54M
−347.5% YoY · −536.1% QoQ
EPS (diluted)
−$0.08
−260.0% YoY · −700.0% QoQ

Source: XBRL data from the OPKO HEALTH, INC. (OPK) Q3 2026 10-Q on SEC EDGAR. USD.

OPKO HEALTH, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $65.4M, up 16% YoY from $56.4M, driven by Eli Lilly royalties and Rayaldee sales
  • Operating loss $31.4M vs $33.6M YoY, equivalent margins of -48.0% vs -59.5%
  • Best segment Global Products: revenue $48.4M, operating income $6.0M vs loss $1.2M
  • Worst segment Innovative Biotech: operating loss $26.8M vs $22.5M, R&D $30.4M vs $26.3M
  • Cash, equivalents and restricted cash $403.2M; operating cash use $99.1M and royalty-note proceeds $123.1M YTD
  • Outlook: liquidity expected sufficient beyond 12 months, with risks from pipeline spending, clinical milestones, financing needs and tariffs

Risk Factors

  • No material changes to risk factors from the most recent Form 10-K
  • Key carried-forward risks remain those disclosed in the Form 10-K, without quarterly updates

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other OPKO HEALTH, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.